HCM
PMN icon

Heights Capital Management’s ProMIS Neurosciences PMN Stock Holding History

Heights Capital Management’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,660
Closed -$643K – 330
2026
Q1 		$643K Buy
+50,660
New +$755K 0.18% 107
2025
Q2 		– Sell
-731
Closed -$12.9K – 179
2025
Q1 		$12.9K Sell
731
-5,677
-89% -$121K 0.01% 91
2024
Q4 		$152K Sell
6,408
-9,068
-59% -$226K 0.08% 63
2024
Q3 		$484K Buy
+15,476
New +$578K 0.36% 37

Other funds holding PMN

JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Heights Capital Management's PMN Position: Q2 2026 in Review

Heights Capital Management sold out of ProMIS Neurosciences (PMN) in Q2 2026, closing a stake of 50,660 shares — an estimated $643K sold.

Heights Capital Management first reported a position in PMN in Q3 2024 and held it in 4 quarters. The position peaked at $643K in Q1 2026. 27 funds tracked by Wall St. Rank hold PMN as of Q2 2026.

  • Heights Capital Management reported no remaining ProMIS Neurosciences position as of Q2 2026 after selling out during the quarter.
  • Heights Capital Management sold 50,660 ProMIS Neurosciences shares in Q2 2026, an estimated $643K.
  • Heights Capital Management first reported a position in ProMIS Neurosciences in Q3 2024 and held it in 4 quarters.
  • Heights Capital Management's ProMIS Neurosciences position peaked at $643K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q2 2026.

Based on Heights Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.